Keratoconus Clinical Trials
Here are the 6 most popular medical studies for keratoconus
Contact Lens
Corneal Gas Permeable Lenses for Keratoconus
This trial is comparing two methods of correcting vision for people with keratoconus, a condition where the shape of the cornea becomes irregular. The study will compare how well each method works and how satisfied patients are with their vision.
Popular filter options for keratoconus trials
Corneal Ectasia Clinical Trials
View 12 Corneal Ectasia medical studies.
Crosslinking Agent
Standard vs. Accelerated Corneal Crosslinking for Keratoconus
This trial will compare two methods of corneal crosslinking, accelerated and standard, to see which is more effective in treating progressive keratoconus or corneal ectasia.
Procedure
Corneal Collagen Crosslinking + Intacs for Keratoconus
This trial will compare two procedures for treating keratoconus, a degenerative eye disease. One procedure uses a collagen crosslinking, while the other uses Intacs. The goal is to determine which procedure is more effective.
Phase 3 Keratoconus Clinical Trials
View 29 phase 3 keratoconus medical studies.
Crosslinking Agent
Standard vs. Accelerated Corneal Crosslinking for Keratoconus
This trial will compare two methods of corneal crosslinking, accelerated and standard, to see which is more effective in treating progressive keratoconus or corneal ectasia.
Procedure
Corneal Collagen Cross-Linking Techniques for Keratoconus
This trial will compare the safety and effectiveness of two different techniques for corneal cross-linking (CXL) in eyes with keratoconus and other corneal ectatic disorders. Subjects will be randomized to receive the CXL treatment with either the Epi-On or Epi-Off technique.
Procedure
Corneal Collagen Crosslinking + Intacs for Keratoconus
This trial will compare two procedures for treating keratoconus, a degenerative eye disease. One procedure uses a collagen crosslinking, while the other uses Intacs. The goal is to determine which procedure is more effective.
Keratoconus Clinical Trials With No Placebo
View 29 keratoconus medical studies that do not have a placebo group.
Crosslinking Agent
Standard vs. Accelerated Corneal Crosslinking for Keratoconus
This trial will compare two methods of corneal crosslinking, accelerated and standard, to see which is more effective in treating progressive keratoconus or corneal ectasia.
Procedure
Corneal Collagen Cross-Linking Techniques for Keratoconus
This trial will compare the safety and effectiveness of two different techniques for corneal cross-linking (CXL) in eyes with keratoconus and other corneal ectatic disorders. Subjects will be randomized to receive the CXL treatment with either the Epi-On or Epi-Off technique.
Corneal Implant
Intacs Inserts for Keratoconus
This trial is for a device that corrects nearsightedness and keratoconus. The device is made of two clear segments from a biomedical material called polymethylmethacrylate, and is available in three thicknesses. Two INTACS inserts may be implanted depending on the orientation of the cone and the amount of myopia and astigmatism to be reduced.
View More Keratoconus Trials
See another 9 medical studies focused on keratoconus.
Frequently Asked Questions
Introduction to keratoconus
What are the top hospitals conducting keratoconus research?
When it comes to cutting-edge clinical trials in the field of keratoconus, several top hospitals are leading the way. One such institution is the Cornea and Laser Eye Institute, Hersh Vision Group located in Teaneck. With three active keratoconus trials currently underway and a total of only three trials conducted thus far, this hospital has made significant strides since recording its first trial for this condition in 2021. Meanwhile, another branch of the same institute also based in Teaneck boasts an equally impressive track record with four completed keratoconus trials and ongoing research efforts spanning over nine years since their initial trial in 2012.
In addition to these remarkable achievements within New jersey, other hospitals across different locations have also contributed significantly to advancing our understanding and treatment options for keratoconus. The Cornea and Laser Eye Institute located solely in Teaneck continues to make notable contributions with three active clinical trials focused on this condition and a history comprising three previous studies dating back to 2010.
Meanwhile, at the UPMC Eye Center situated in Pittsburgh, groundbreaking work is being carried out with one active keratoconus trial currently ongoing alongside four previously conducted experiments that began as early as 2012. Similarly, at the Cornea Associates of Texas based in Dallas, researchers are dedicatedly exploring new avenues for treating keratoconus through one current clinical trial while having successfully completed four earlier investigations starting from as far back as 2009.
These esteemed institutions not only provide hope for individuals living with keratoconus but also serve as beacons of progress within ophthalmology worldwide. By constantly pushing boundaries through rigorous research endeavors and innovative approaches, they contribute towards improving vision outcomes for countless patients affected by this progressive eye disorder
Which are the best cities for keratoconus clinical trials?
When it comes to keratoconus clinical trials, several cities are at the forefront of research and innovation. Teaneck, New jersey leads with 10 active trials exploring treatments like Riboflavin drops and WFG Scleral Lenses. Chicago, Illinois follows closely behind with 4 ongoing studies focusing on Corneal gas permeable lenses. Dallas, Texas has 2 active trials investigating PXL-330 Platinum device for crosslinking with Peschke riboflavin solution and Intacs Device. Lastly, Boston, Massachusetts and Indianapolis, Indiana each have 2 active trials studying different approaches such as ex vivo cross-linking of donor corneal tissue and accelerated treatments using the PXL-330 Platinum device/Riboflavin. These cities offer individuals with keratoconus access to cutting-edge clinical trials that aim to improve treatment options for this condition.
Which are the top treatments for keratoconus being explored in clinical trials?
Keratoconus, a progressive eye disorder, has seen promising advancements in clinical trials. Leading the pack is the PXL-330 Platinum device, which utilizes Peschke riboflavin solution for crosslinking. This innovative treatment is currently being explored in two active trials specifically dedicated to keratoconus and has been listed since 2019. With its potential to halt the progression of this condition, it offers hope to individuals dealing with the challenges of keratoconus and paves the way for further breakthroughs in treatment options.
What are the most recent clinical trials for keratoconus?
Exciting advancements in the field of keratoconus treatment have emerged through recent clinical trials. Pulsed lighting therapy has shown promise in improving the condition, with Phase 1 and Phase 2 studies demonstrating positive outcomes. Similarly, NXL Energy 3 has undergone Phase 1 and Phase 2 trials, offering potential benefits for individuals with keratoconus. Continuous UVA treatment, investigated during a Phase 3 trial, holds promise as well. Additionally, riboflavin drops administered every two minutes (Phase 3) and corneal collagen cross-linking using a Riboflavin/Dextran solution (Phase 3) have exhibited encouraging results. These latest developments bring hope to those affected by keratoconus and signify progress towards improved therapeutic options for this eye disorder.
What keratoconus clinical trials were recently completed?
In recent years, several noteworthy clinical trials investigating potential treatments for keratoconus have concluded. One such study, sponsored by Sight Medical Doctors PLLC, examined the effectiveness of Dextenza and was completed in February 2020. Similarly, Cornea Associates of Texas sponsored a trial that focused on the PXL-330 Platinum device for crosslinking with Peschke riboflavin solution, which concluded in January 2020. These trials mark important milestones in the ongoing research efforts to enhance treatment options for individuals with keratoconus.